

## ASX Release

---

# ZELIRA THERAPEUTICS FEASIBILITY STUDY UPDATE

**PERTH, AUSTRALIA – 16 January 2021:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, announces that Zelira Therapeutics have elected not to proceed with further work and exercise their option to progress from a feasibility study into a global development and licensing agreement.

SUDA will continue to focus on its partnership with Cann Pharma Australia to develop an oral spray formulation for their medical grade cannabis product. SUDA will also continue to focus on its existing partnerships for other drug products and to evaluate additional technologies in the oncology and central nervous space to add to its portfolio.

For and on behalf of the Board and for further information please contact:

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

[mbaker@sudapharma.com](mailto:mbaker@sudapharma.com)

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)